PT - JOURNAL ARTICLE AU - Mukae, Hiroshi AU - Yotsuyanagi, Hiroshi AU - Ohmagari, Norio AU - Doi, Yohei AU - Imamura, Takumi AU - Sonoyama, Takuhiro AU - Fukuhara, Takahiro AU - Ichihashi, Genki AU - Sanaki, Takao AU - Baba, Keiko AU - Takeda, Yosuke AU - Tsuge, Yuko AU - Uehara, Takeki TI - A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part AID - 10.1101/2022.05.17.22275027 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.17.22275027 4099 - http://medrxiv.org/content/early/2022/05/17/2022.05.17.22275027.short 4100 - http://medrxiv.org/content/early/2022/05/17/2022.05.17.22275027.full AB - For the treatment of coronavirus disease 2019 (COVID-19), antiviral agents that can achieve rapid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reduction are warranted. This double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and safety of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection. Sixty-nine patients enrolled from 56 sites were randomized (1:1:1) to orally receive 5-day ensitrelvir fumaric acid (375 mg on day 1 followed by 125 mg daily or 750 mg on day 1 followed by 250 mg daily) or placebo and followed up until day 28. The primary outcome was change from baseline in SARS-CoV-2 viral titer. A total of 16, 14, and 17 patients in the ensitrelvir 125 mg, ensitrelvir 250 mg, and placebo groups, respectively, were included in the intention-to-treat population (mean age: 38.8, 40.4, and 38.0 years, respectively). On day 4, the change from baseline in SARS-CoV-2 viral titer (log10 50% tissue culture infectious dose/mL) in patients with positive viral titer and viral RNA at baseline was greater with ensitrelvir 125 mg (mean [standard deviation], −2.42 [1.42]; P = 0.0712) and 250 mg (−2.81 [1.21]; P = 0.0083) versus placebo (−1.54 [0.74]), and ensitrelvir treatment reduced SARS-CoV-2 RNA by −1.4 to −1.5 log10 copies/mL versus placebo. All adverse events were mild to moderate. Ensitrelvir treatment demonstrated rapid SARS-CoV-2 clearance and was well tolerated in patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection (Japan Registry of Clinical Trials identifier: jRCT2031210350).Competing Interest StatementH. Mukae has received funding relevant to the submitted work from Shionogi and grants from Taisho Pharma; lecture fees from Pfizer, MSD, Shionogi, and Taisho Pharma; and advisory fees from Pfizer, MSD, and Shionogi outside the submitted work. H. Yotsuyanagi has received consulting fees from Shionogi, lecture fees from Shionogi and ViiV Healthcare, and travel support from Shionogi outside the submitted work. He serves as an advisory board member of Shionogi and President of the Japanese Society of Infectious Diseases. Y. Doi has received grants from Shionogi and Entasis; consulting fees from Shionogi, Meiji Seika Pharma, Gilead Sciences, GSK, MSD, Chugai, and bioMerieux; and lecture fees from MSD, AstraZeneca, Shionogi, and Teijin Healthcare outside the submitted work and serves as an advisory board member of FujiFilm. T. Imamura, T. Sonoyama, T. Fukuhara, G. Ichihashi, T. Sanaki, K. Baba, Y. Takeda, Y. Tsuge, and T. Uehara are full-time employees of Shionogi & Co., Ltd. and may have stocks or stock options. N. Ohmagari declares no conflict of interest.Clinical TrialjRCT2031210350Funding StatementThis study was sponsored by Shionogi & Co., Ltd. and financially supported by the Japan Agency for Medical Research and Development.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the institutional review boards of all participating institutions listed in Table S1. All patients or their legally acceptable representatives provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesShionogi & Co., Ltd. is committed to disclosing the synopses and results of its clinical trials and sharing clinical trial data with researchers on reasonable request. For further details, please refer to the websites of Shionogi & Co., Ltd. (https://www.shionogi.com/shionogi/global/en/company/policies/shionogi-group-clinical-trial-data-transparency-policy.html) and Vivli (https://vivli.org/).